We are an oncology company developing next-generation antibody-drug conjugates (“ADCs”) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Our lead payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships WuXi Biologics/XDC: GMP manufacturing and IND-enabling work (Dec 2025); Whitehawk Therapeutics: strategic research collaboration (Jul 2026) evaluating PH1 payload with Whitehawk's topoisomerase I inhibitor ADC platform (preclinical)
Indications
Solid tumors (incl. lung, breast, bladder, head & neck, gastric)(Preclinical)
Catalysts
— middle of 2027
Status note Lead program. Trop-2-targeting ADC combining PH1 spliceosome-modulating payload with a proprietary non-cleavable linker. IND-enabling activities underway; GMP manufacturing initiated Dec 2025. 10-K (earlier) guided FIH Phase 1 by late 2026/early 2027; 10-Q restates projection as clinical trials by middle of 2027.
Status note CEACAM5-directed ADC utilizing PH1 payload; earlier in development than lead program. Company plans to advance toward lead product candidate status.
Nomacopan
Stage not disclosed · ActiveModality: bispecific protein
Target C5/leukotriene B4
Indications
not disclosed(Stage not disclosed)
Status note Legacy program suspended December 2024; company seeking a collaborative partner for continued development. Not terminated. Stage/indication detail appears only in the 10-K fallback section and is not populated.
PAS-nomacopan
Stage not disclosed · Active
Target C5, LTB4
Indications
not disclosed(Stage not disclosed)
Status note Legacy program suspended December 2024; company seeking a collaborative partner for continued development. Not terminated. Stage/indication detail appears only in the 10-K fallback section and is not populated.
PHP-303
Stage not disclosed · Active
Target neutrophil elastase
Partnerships Bayer Pharmaceuticals: rights and associated know-how acquired (Mar 2017)
Indications
not disclosed(Stage not disclosed)
Status note Legacy program suspended December 2024; company seeking a collaborative partner for continued development. Not terminated. Stage/indication detail appears only in the 10-K fallback section and is not populated.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.